Personalized mRNA cancer vaccine meets Phase 3 melanoma endpoints
A personalized mRNA neoantigen therapy from Moderna and Merck met both major Phase 3 efficacy endpoints in resected high-risk melanoma, but the size of the benefit is not yet public.
Personalized mRNA cancer vaccine meets Phase 3 melanoma endpoints Read More »